Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 6;11(5):1806–1817. doi: 10.1007/s13346-020-00868-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — Paclitaxel levels in lung (a) and plasma (b) after inhaled NanoPac treatment. Male Sprague–Dawley rats (6–8 weeks old) were administered paclitaxel on a single occasion in one of three treatment arms (n = 30 each): inhaled submicron particle paclitaxel in a nose-only exposure at a low-dose of 0.38 mg/kg or a high dose of 1.18 mg/kg, or intravenous nab-paclitaxel administered via tail vein injection at 2.9 mg/kg. Three animals from each arm were sacrificed at 0.5, 6, 12, 24, 48, 72, 120, 168, 240, and 336 h post exposure for lung tissue and plasma collections. Lung tissue (a) and plasma (b) were assayed via ultra-performance liquid chromatography tandem mass spectrometry to quantify paclitaxel concentration as a function of time with a lower level of quantification of 50 ng/g and 1 ng/mL, respectively (mean ± 1SEM) [6]. Reprinted by permission from Mary Ann Liebert, Inc.: [Mary Ann Liebert] [Journal of Aersol Medicine and Pulmonary] [Pharmacokinetic profile of inhaled submicron particle paclitaxel (NanoPac) in a rodent model, James Verco et al.] [2019]